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NeovascularizationAge-related macular degeneration (AMD) is a leading cause of central blindness in the elderly population.
The wet type of AMD is characterized by extensive growth of new vessels. One of the effective strategies to
treat wet AMD is to limit the choroidal neovascularization (CNV). We studied the effects of adiponectin peptide
I (APNpI) on new vessel growth in laser-induced rat model of wet AMD and on rat choroidal endothelial cell
(CEC) culture. CNV size and vessel density were investigated by microscopy. Immunohistochemical staining
(IHC) for vonWillebrand Factor (vWF), APN, APN receptors 1 (AdipoR1), 2 (AdipoR2), VEGF, VEGF receptor
2 (VEGF-R2), proliferating cell nuclear antigen (PCNA) was performed in CNV area. ThemRNA expression of
VEGF and VEGF-R2 in RPE-choroid was investigated by RT-PCR and real-time PCR. APNpI inhibited area of
CNV by 4 fold, number of vWF positive vessels by 99% and area of subretinal tissue by 40%. The expression
of VEGF and VEGF-R2 at mRNA and protein levels decreased after APNpI treatment in vivo. Proliferative
index (PCNA) was 5 folds less in laser spots of APNpI treated rats compared to controls. In conclusion,
APNpI inhibited formation of new vessels in rat model of CNV by decreasing VEGF, VEGF-R2 expression
and cell proliferation. Thus, APNpI may have potential therapeutic use for AMD treatment since it signiﬁ-
cantly inhibited CNV.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Age-related macular degeneration (AMD) is a leading cause of
blindness in the elderly population [1–3]. The wet type of AMD is
characterized by extensive growth of new vessels [2–5]. One of the
effective strategies in treatment of AMD in humans is to limit choroidal
neovascularization (CNV) by acting on VEGF related signaling pathway
which is involved in pathogenesis of AMD [3–5]. Anti-VEGF drugs are
successfully being used for inhibition of CNV [4]. However, these
drugs have some serious side effects: endophthalmitis, rhegmatoge-
nous retinal detachment, retinal tear, uveitis, and vitreous hemorrhage
[6]. Therefore development of new drugs which may be more effective
and have fewer side effects is necessary as an alternative to current
treatments.
One of the possible candidates for treatment of AMD in humans
may be adiponectin (APN) or peptides derived on the structural
basis of the APN. APN is a plasma protein, secreted predominantly
by adipose cells and mimics many metabolic actions of insulin [7,8].
The expression of APN was shown in numerous tissues suggesting the
importance of APN in regulation of local processes [8–10]. Additionally
to its metabolic functions, APN acts as a regulator of angiogenesis and
proliferation [11–19]. APN shares sequence homology with a family of+1 501 686 8316.
l rights reserved.proteins showing a modular design containing a C-terminal comple-
ment factor C1q-like globular domain and the C-terminal globular
domain [20]. However, the mechanism by which APN acts is poorly
understood. The aim of this study is to understand the role of APN
peptide I on CNV in rats and to investigate the expression of VEGF,
VEGF receptor 2 in the retinal pigment epithelium (RPE) and choroid.
In the present studywe have shown the role of APN peptide I in the reg-
ulation of VEGF and VEGF receptor 2 in rat eye. As an angiogenesis in-
hibitor, APN may also have therapeutic implications in the treatment
of age related macular degeneration.
2. Methods
2.1. Animals
Male Brown Norway rats, 6–7 weeks old, from Harlan Sprague
Dawley, Inc. were used. This study was approved by the Institutional
Animal Care and Use Committee (IACUC), University of Arkansas for
Medical Sciences (UAMS), Little Rock, AR.
2.2. Choroidal endothelial cells (CECs) culture and APNpI administration
CECs were isolated from eyes as described [21] with modiﬁcations.
Brown Norway rats (n=3 rats) were sacriﬁced and eyes were removed
under sterile conditions. Eyes were treated with 70 °C ethanol for 30 s
andwashedwithDulbecco's phosphate buffered saline (DPBS,Mediatech,
Manassas, VA) for 1 min (3 times). Eyes were dissected and anterior part
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from sclera by scraping and transferred to DPBS. RPE-choroid tissue
was treated with 0.25% trypsin (HyClone, Logan, UT) for 30 min.
RPE-choroid cells were incubated in selective medium MCDB-1 with
fetal bovine serum and antibiotics (VEC Technologies, Rensselaer, NY) in
25cm2 ﬂasks under condition of 5% CO2 and 37 °C. After 2 passages cells
were investigated for presence of endothelial cell markers CD31, von
Willebrand Factor (vWF) and Isolectin IB4 (ILIB4). We used CD31+
vWF+ILIB4+ endothelial cells, from 3rd to 5th passage (split ratio 1:3),
50 cells per 1 mm2 of surface area.
Adiponectin peptide I (APNpI, NH2-KDKAVLFTYDQYQEKNVD-COOH,
GenScript, and Piscataway, NJ) was dissolved in sterile deionized water.
Concentration 80 μg/mL of APNpI was prepared using MCDB-1 medium.
Treatment of CECs with APNpI was performed during 12 h. All experi-
ments were repeated 3 times.
2.3. Induction of CNV in rats and APN peptide I administration
Animals were divided into 3 groups. CNV was induced by Argon
laser (Lumenis Inc., Santa Clara, CA) as previously described [22–26].
Three laser spots (spot size — 50 μm; duration — 0.05 s; power —
360 mW) were placed in each eye close to the optic nerve. Groups 1
(n=45 rats) and 2 (n=45 rats) were lasered and group 3 (n=20
rats) was not treated with laser and used as a control. We synthesized
5 peptides (each of 18 amino acids) fromglobular region of adiponectin,
whichhas nohomologywith the complement component 1q (C1q).We
tested all 5 peptides but found that 2 mg/animal/day of adiponectin
peptide I (APNpI, NH2-KDKAVLFTYDQYQEKNVD-COOH, Peptide Bio-
chemical Research Inc., Seattle) has maximum effect on rats. APNpI
was injected intraperitoneally (dose of 2 mg/animal/day) 1 day before
laser treatment and then every day until animals were sacriﬁced.
Group 1 received PBS, group 2 was injected with APNpI and group 3
was not injected.
2.4. CNV size evaluation
Size of CNV was determined as described before [22–26]. Brieﬂy,
10 days after laser treatment, 5 animals from group 1 (PBS injected)
and group 2 (APNpI injected) were anesthetized with ketamine and
xylazine, perfused with 2 ml of PBS containing 50 mg/ml ﬂuorescein
isothiocyanate labeled dextran (average molecular mass 2,000,000;
Sigma-Aldrich, St. Louis, MO) and sacriﬁced. Eyes were ﬁxed in nor-
mal buffered formalin (Sigma-Aldrich, St. Louis, MO) for 4 h. After
dissection of the eyes, the RPE-choroid-sclera complexes were
stained for elastin using antibody (Santa Cruz Biotechnology, CA)
and ﬂat mounted in water soluble Durcupan (Sigma-Aldrich, St.
Louis, MO). Images of laser injured areas were captured using confo-
cal microscope LSM510 (Carl Zeiss, Jena GmbH). The size of CNV was
determined by morphometric analysis using the ImageJ program
(National Institutes of Health, Bethesda, Maryland USA). Areas of
green (FITC-dextran perfused vessels or CNV) and red ﬂuorescence
(elastin positive) were measured and percentage of CNV area was
calculated.
2.5. Histology
CNVwas induced in rats andAPNpI or PBSwas injected as described.
Eyes were ﬁxed 10 days after laser treatment in 10% formalin solution
(Sigma-Aldrich, St. Louis, MO) for 24 h, dehydrated in ethanol and
embedded in parafﬁn. Four-micron serial sections were cut. After
deparafﬁnization in xylene and hydration sections were stained
with hematoxylin and eosin (Electron Microscopy Sciences, Hatﬁeld,
PA). Stained sections were dehydrated in ethanol, cleaned in xylene
and mounted in Permount (Electron Microscopy Sciences, Hatﬁeld,
PA). After drying for at least 48 h, sections were used for morphologicalanalysis. Images of laser injured area of the choroidwere captured using
QImaging GO-5 camera (Surrey, BC, Canada) and Olympus microscope.
2.6. Immunohistochemistry and immunocytochemistry
We used abovementioned serial sections for immunohistochemical
(IHC) studies and cultured CECs for immunocytochemical (ICC) investi-
gations. Goat polyclonal anti-rat VEGF164 antibody (R&D Systems,
Minneapolis, MN), goat anti-adiponectin antibody (R&D Systems,
Minneapolis, MN), rabbit polyclonal anti-VEGF receptor 2 antibody
(Afﬁnity Bioreagents, Golden, CO), rabbit anti-vonWillebrand Factor
endothelial marker (Afﬁnity Bioreagents, Golden, CO), goat poly-
clonal anti-PCNA antibody (Biovision, Mountain View, CA), rabbit
anti-adiponectin receptor R1 and R2 serum (both from Phoenix
Pharmaceuticals, Belmont, CA), rabbit anti-adiponectin R1 antibody
(Abcam, Cambridge,MA), goat anti-CD31 antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA) were used as primary antibody. For double im-
munohistochemical staining we used secondary rabbit anti-goat IgG
(H+L)-FITC, rabbit anti-goat IgG (H+L)-AF594, goat anti-rabbit IgG
(H+L)-FITC and Isolectin IB4 AF594 conjugate purchased from Invi-
trogen (South San Francisco, CA). Sections were mounted in ProLong
antifade reagent (Invitrogen, South San Francisco, CA). We also used
secondary biotinylated anti-goat or anti-rabbit afﬁnity puriﬁed IgG
(H+L), Vectastain Elite ABC Kit with horse-radish peroxidase, Vector
VIP substrate KIT for peroxidase which gives purple color of speciﬁc
staining and Vector Methyl green nuclear counterstain (all fromVector
Laboratories, Burlingame, CA). For immunocytochemical study CECs
were incubated in Lab-Tek chamber slide system (Nalge Nunc, Naper-
ville, IL) in MCDB-1 complete medium for 24 h in 5% CO2 atmosphere
and 37 °C temperature. Cells were ﬁxed in methanol for 20 min on ice,
washed with DPBS and stained using endothelial cell markers CD31,
vonWillebrand Factor (vWF) and Isolectin IB4 (ILIB4). Control stains
were performed with isotype matched control antibodies at concen-
trations similar to those of the primary antibodies and staining by omis-
sion of the primary or secondary antibodies. Sections were mounted
using Permount (Electron Microscopy Sciences, Hatﬁeld, PA). Cell
observation and capturing of sections were made using an Olympus
microscope equipped with QImaging Go-5 camera (Surrey, BC,
Canada).
2.7. Colocalization of adipoR1 receptors and APNpI
We investigated binding of APNpI to RPE-choroid tissue in vivo
and to endothelial cells in vitro using method of double IHC or ICC.
We used FITC labeled APNpI (APNpI-FITC, GenScript, and Piscataway,
NJ). We dissolved APNpI-FITC in sterile deionized water and prepared
80 μg/mL solution of APNpI-FITC in DPBS. We induced CNV in rats as
described above and injected 5 μL of APNpI-FITC or DPBS subretinal to
naïve rats and laser treated animals on day 7 post-laser. We sacriﬁced
animals in 1 h after injection, harvested eyes and placed them in
Tissue-Tek O.C.T compound (Sakura Finetek, Torrance, CA). The eyes
were snap frozen using Frostbite (Surgipath Medical Industries,
Richmond, IL) and stored at −80 °C. Cryosections (20 μm) were cut
and ﬁxed with ice cold methanol for 20 min. Sections were addition-
ally stained for adipoR1 by IHC. Rat CECs were incubated in Lab-Tek
chamber slide system (Nalge Nunc, Naperville, IL) in MCDB-1 com-
plete medium for 24 h in 5% CO2 atmosphere and 37 °C temperature.
Cells were ﬁxed in methanol for 20 min on ice, washed with DPBS
and treated with 80 μg/mL of APNpI-FITC for 1 h at 37 °C in humid
chamber. Cells additionally were stained for adipoR1 by ICC. Sections
and cells were mounted in ProLong antifade reagent with DAPI (Invi-
trogen, South San Francisco, CA).Weused ZEISS LSM510 laser confocal
microscope set up with Beam Splitters as follows: 488 nm laser (25%)
window 505–550 nm, 561 nm laser (25%) window 575–615 nm. Eight
bit images were obtained using the microscope in sequential mode
with line average of 16 and format 1024×1024 pixels and in one single
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and Immersol 518 F oil (ne=1.518 (23 °C) Carl Zeiss, Oberkochen,
Germany).
2.8. Semiquantitative scoring of IHC staining
We investigated sections of naïve or laser treated rats on day 10 post
laser injury (n=5 rats in each group and 15 spots in each group), that
were stained for AdipoR1 andAdipoR2. Semiquantitative scoring of pos-
itive signal in choroidal vessels and RPE cells located in spot area was
performed as described before [15]. The intensity of stainingwas graded
from 0 to 3 (0— no staining; 1 — faint; 2 —moderate; 3 — intense).
2.9. Vessel density quantiﬁcation
We investigated APNpI and PBS injected animals (5 animals or 15
spots per group) on day 10 post laser injury. We captured hematoxylin
and eosin stained sections (3 sections per one laser spot) and close
sections stained by IHC for endothelial marker von Willebrand Factor.
Vessels in the laser injured area were identiﬁed by morphological
signs (oval shaped structures with lumen or blood cells inside) and
presence of speciﬁc staining for von Willebrand Factor. Laser injured
areaswere selectedmanually using the ImageJ program (National Insti-
tutes of Health, Bethesda, MD). Number of vessels in this area was
counted and number of vessels per 1 mm2 was calculated.
2.10. Quantiﬁcation of immunoﬂuorescence in laser spots
Parafﬁn sections (5 animals or 15 spots per group) of IHC stained
for VEGF, VEGF-R2 and endothelial marker isolectin IB4 were investi-
gated using ZEISS LSM 510 laser confocal microscope. Composite im-
ages of differential interference contrast (DIC), red (endothelial cells)
and green (VEGF or VEGF-R2) were captured. Isolectin IB4 positive
vessels and RPE cells were identiﬁed using DIC images and manually
selected. Mean intensity of VEGF or VEGF-R2 positive signal was mea-
sured separately in 1) RPE cells, 2) isolectin IB4 positive vessels and
3) the rest of the choroid (in naïve animals) or subretinal tissue (in
laser treated rats) using the ImageJ program (National Institutes of
Health, Bethesda, MD).
2.11. Quantiﬁcation of PCNA proliferative index
We used sections of APNpI and PBS treated animals (n=5 rats in
each group) sacriﬁced on day 10 post laser injury. Sections were IHC
stained for PCNA. Three sections from each laser injured area were
captured, totally 15 laser spots sections per group were investigated.
The number of PCNA positive nuclei (purple color) and total number
of nuclei (purple and green color) in laser injured area were counted
using ImageJ program (National Institutes of Health, Bethesda, MD)
and the percentage (%) of PCNA-positive nuclei was calculated.
2.12. RT-PCR analysis
Five animals from each group were sacriﬁced and RPE-choroids
were harvested from the enucleated eyes. Total RNA was extracted
from the tissue with RNeasy Mini Kit (QIAGEN, Valencia, CA). Equal
amounts of the total RNA (0.1 μg) were used to detect the mRNA
levels of β-actin, VEGF and VEGF-R2 by RT-PCR using the reagents
from Applied Biosystems (Foster City, CA). Oligonucleotide primers
were obtained from Integrated DNA Technologies (San Diego, CA).
The negative controls consisted of omission of RNA or reverse transcrip-
tase from the reactionmixture. PCR products were analyzed on a 1% aga-
rose gel and were examined by using Quantity One (Bio-Rad, Hercules,
CA). RT-PCR was conducted using the following primers: β-actin (F, 5′-
GCG CTC GTC GTC GAC AAC GG-3′; R, 5′-GTG TGG TGC CAA ATC TTC
TCC-3′); VEGF (F, 5′-GCG GGC TGC TGC AAT GAT-3′; R, 5′-TCA CCG CCTTGG CTT GTC AC-3′); VEGF-R2 (F, 5′-GCT TGC CTT ATG ATG CCA GCA
AGT-3′; R, 5′-GGG CCA AGC CAA AGT CAC AGA TTT-3′). The experiment
was repeated three times with similar results.2.13. Real-time quantitative RT-PCR (RT-qPCR)
Naïve non treated animals and animals on day 10 post laser injury
were sacriﬁced and RPE-choroid tissue harvested from the enucleated
eyes. Total RNAwas puriﬁed using the RNeasymini kit (Qiagen, Valencia,
CA), and cDNA was synthesized using the iScript cDNA synthesis kit
(Bio-Rad, Hercules, CA) with 0.5 μg of total RNA according to the man-
ufacturer's recommendations. qPCR was performed with primers spe-
ciﬁc for rat APN, VEGFA, VEGF-R2 and β-actin using iQ SYBR Green
Supermix in an iQ5 real-time PCR detection system (Bio-Rad, Hercules,
CA). The primers were designed and ordered from Integrated DNA
Technologies (Coralville, IA). The primer sequences usedwere as follows:
rat APN, 5′-CGG TAT CCC ATT GTG ACC AG-3′ (forward) and 5′-CGC TCC
TG TTC CTC TTA ATC C-3′ (reverse); rat VEGF, 5′-CTC TTT TCT CTG CCT
CCA TGA-3′ (forward) and 5′-CCA TTG AAA CCA CTA ATT CTG TCC-3′ (re-
verse); VEGF-R2 5′-GAG TAG CCA TGC ACC GAA T-3′ (forward) and 5′-
CGG CTG TCC ATG AAA GTG AA-3′ (reverse);and rat β-actin, 5′-AAC
CCT AAG GCC AAC CGT GAA A-3′ (forward) and 5′-AGG CAT ACA GGG
ACA ACA CA-3′ (reverse). Pilot real-time RT-qPCR experiments were per-
formed to determine the optimal condition for each primer. All real-time
RT-qPCR experimentswere performed induplicate. The primer speciﬁcity
of the ampliﬁcation product was conﬁrmed by melting curve analysis of
the reaction products using SYBR Green as well as by visualization on
ethidium bromide-stained agarose (1.5%) gels. The housekeeping gene
β-actin was used as an internal control, and the gene-speciﬁc mRNA ex-
pression was normalized against β-actin expression. iQTM5 optical
system software (Bio-Rad; version 2.0) was used to analyze real-time
RT-qPCR data and derive threshold cycle (CT) values according to the
manufacturer's instructions. The ΔΔCT method was used to transform
CT values into relative quantities with S.D. The same software was
used to calculate the normalized expression of the gene of interest,
using β-actin as reference gene, and the results were expressed as nor-
malized fold expression.2.14. Semi-quantitative Western blot analysis
Total protein was extracted from the pooled RPE-choroid tissue. The
tissue was homogenized and solubilized in ice-cold PBS containing pro-
tease inhibitors and detergent NP-40. Electrophoresis was performed
on 7.5% SDS-PAGE slab gel and the separated proteins were transferred
to polyvinylidene diﬂuoride (PVDF) membranes. The blots were
blocked with 5% non-fat dry milk. Goat polyclonal anti-rat VEGFA anti-
body (R&D Systems, Minneapolis, MN) and rabbit polyclonal anti-VEGF
receptor 2 antibody (Afﬁnity Bioreagents, Golden, CO) was used as the
primary antibodies and the blots were incubated overnight at +4 °C.
The control blots were reacted with equivalent concentration of isotype
matched puriﬁed IgG. Blotswere developed using the enhanced chemilu-
minescence Western blotting detection system “ECL+Plus” (Amersham
Pharmacia Biotech, Arlington Heights, IL) according to manufacturer's
recommendations. Quantiﬁcation of VEGF, VEGF-R2 and β-actin was ac-
complished by analyzing the intensity of the bands using Quantity one
4.2.0 (Bio-Rad). The experiment was repeated three times with similar
results.2.15. Statistical analysis
Comparison between groups was performed with Statistica pro-
gram (StatSoft, Tulsa, OK) using ANOVA/MANOVA analysis (post-hoc
comparisons, Newman–Keuls test). Data presented as mean±SE.
Signiﬁcance was deﬁned at pb0.05.
Fig. 1. Localization and expression of adiponectin receptors and adiponectin in rat CNV. Eyes from naïve rats and laser treated animals were sacriﬁced on day 10 post laser injury and
IHC stained for adiponectin. Positive staining is purple (red arrow), nuclei are green. Representative images of IHC staining for AdipoR1 (A, E) and AdipoR2 (B, F). RPE cells (black
arrow), choroidal vessels (v) and other cells were positive (purple color) for adiponectin receptors. Semiquantitative scoring of IHC for AdipoR1 (I) and AdipoR2 (J) in RPE cells and
choroidal vessels. Expression of AdipoR1 increased in RPE cells and choroidal vessels on day 10 after laser compared to naïve control. Adiponectin was detected in endothelial cells
of choroidal vessels (v) of naïve animals (C, D) and in laser spots (G, H). Expression of APN in laser injured and naïve control RPE-choroid tissue was investigated by real-time PCR.
Signiﬁcant increase of APN mRNA was found in RPE-choroid with laser induced CNV compared to naive control (K). Bar=25 μm for images C and G; bar=7 μm for images D and H.
Images D and H are the enlargement of area shown in rectangle on images C and G, respectively. Bar for images A, B, E and F is 20 μm.
Fig. 2. Binding of APNpI to AdipoR1 positive cells. Laser confocal microscopic images of cryosections of naïve control (A, B), CNV on day 7 post laser injury (C, D) and CECs in culture
(E, F). Yellow color represents colocalization of APNpI-FITC (green color) and AdipoR1 (red color). Accumulation of APNpI was found predominantly on cells with adipoR1 expression.
There was very low autoﬂuorescence of the tissues (B, D, F). Bar for A–D and E–F is 10 μm.
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Fig. 3. Effect of APNpI on laser-induced CNV. (A, B) Laser confocal microscopic images of ﬂat mounted RPE-choroid-sclera on day 10 post laser injury. Green color shows FITC-dextran
perfused vessels and red color is IHC staining for elastin. There was signiﬁcant decrease of CNV size after treatment with APNpI compared to the control (C). Bar for all images is 40 μm.
Fig. 4. Histological investigation of laser spot area of PBS (A, C) and APNpI (B, D) treated animals. Representative images of parafﬁn section stainedwith hematoxylin and eosin (A, B) and
IHC for vonWillebrand Factor endothelialmarker (C, D). Vesselsmarkedwith arrow.Wedetermined signiﬁcant decrease of area of subretinal tissue (E) and vessel density (F) in laser spot
of APNpI treated rats compared to PBS treated animals. Bar for all images is 20 μm.
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3.1. Expression of adiponectin receptors and adiponectin in rat CNV
We investigated the expression of APN and its receptors in naïve and
laser treated rat eyes on day 10 post laser injury using method of IHC.
Adiponectin receptors R1 (AdipoR1) and R2 (AdipoR2) were found in
RPE cells and choroidal vessels of naïve animals (Fig. 1A, B) and in the
CNV areas of laser treated rats (Fig. 1E, F). Semiquantitative evaluation
of IHC staining on parafﬁn sections showed that the expression of
AdipoR1 was signiﬁcantly increased on day 10 after laser treatment
compared to naïve control (Fig. 1I). We did not ﬁnd difference of
staining for AdipoR2 between experimental groups (Fig. 1J). Positive
staining for APN was localized in large and medium sized vessels of
the naïve rat choroid (Fig. 1C, D). On day 10 post laser injury intensity
of APN staining in choroid vessels increased (Fig. 1G, H) compared to
naïve rats. Some APN positive new vesselswere located in the subretinal
tissue (Fig. 1G). Real-time PCR analysis of RPE-choroid tissue detected
increased expression of APN mRNA in the laser treated animals com-
pared to the naïve animals (Fig. 1K).Fig. 5. Effect of APNpI on VEGF expression. (A) RT-PCR products for VEGF in RPE-choroid-scl
injury. APNpI decreased VEGF mRNA (327 bp) expression. A strong band for β-actin (335 bp)
Western blot analysis of RPE-choroid tissue shows that laser treatment increases expression of
of VEGFAmRNAexpression in choroidal endothelial cells showed signiﬁcant down regulation of
for VEGF (green color). (I–K) Merged DIC (black and white), VEGF (green) and Isolectin IB4 (r
vessels (non pigmented oval shaped structures, positively marked with Isolectin IB4 in red
(L), choroidal vessels (M) and the rest of the choroid or subretinal tissue (N) was done. VEG
injury (L, M, N). APNpI administration decreased expression of VEGF in RPE cells, vessels3.2. Colocalization of adipoR1 receptors and APNpI
Weobserved binding of APNpI-FITC to RPE-choroid tissue in vivo and
to CECs in vitro. APNpI was colocalized with adipoR1 (Fig. 2A, C, E).
However, no background autoﬂuorescence of the tissues and cells was
observed (Fig. 2B, D and F).3.3. Effect of APNpI on size of CNV
In the present study we investigated the effects of systemic admin-
istration of APNpI in ratmodel of CNV. PBS treated animals hadwell de-
veloped CNV complex and FITC-dextran perfused vessels occupied 25%
of laser spot. After APNpI treatment size of CNV decreased 4 fold
compared to control (Fig. 3). To conﬁrm anti-angiogenic effect of
APNpI we investigated serial parafﬁn sections of rat eyes stained
with hematoxylin/eosin and endothelial marker vWF. APNpI treated
animals on day 10 post laser injury had 40% smaller size of subretinal tis-
sue and decreased density of vessels (2 folds) compared to the control
(Fig. 4).era of naïve, APNpI and PBS treated rats (n=6 rats in each group) on day 10 post laser
indicates equal amounts of RNA in each lane. (C) Densitometric analysis of PCR products.
VEGFA (23 kDa) in RPE-choroid compared to naïve control (B, D). Real-time PCR analysis
VEGFA after APNpI (80 μg/mL) treatment (E). (F–H)Representative images of IHC staining
ed) images helps distinguish RPE cells (pigmented cells in upper part of each image) and
color) and laser injured area. Quantiﬁcation of mean intensity of ﬂuorescence in RPE
F expression signiﬁcantly increased in all investigated structures on day 10 post laser
and laser injured area compared to PBS treated group. Bar for all images is 25 μm.
Fig. 6. Effect of APNpI on VEGF-R2 expression. (A) Ethidium bromide stained gel showing VEGF-R2 mRNA in RPE-choroid of naïve, APNpI and PBS treated rats on day 10 post laser
injury. APNpI decreased VEGF-R2 mRNA (696 bp) on day 10 after laser treatment. (C) Densitometric analysis of PCR products. Western blot analysis of RPE-choroid tissue shows
that laser treatment increases expression of VEGF-R2 (180 kDa) in RPE-choroid compared to naïve control (B, D). Real-time PCR analysis of VEGF-R2 mRNA expression in choroidal
endothelial cells showed no signiﬁcant changes of VEGF-R2 expression after APNpI (80 μg/mL) treatment (E). (F–H) Representative images of laser confocal microscopy of IHC
staining for VEGF-R2 (green color) and (I–K) merged DIC (black and white), VEGF (green color) and Isolectin IB4 (red color) images. Quantiﬁcation of mean intensity of immuno-
ﬂuorescence in RPE (L), choroidal vessels (M) and choroid or subretinal tissue (excluding vessels) (N). On day 10 post laser injury expression of VEGF-R2 increased in RPE cells and
subretinal tissue compared to naïve control. APNpI administration decreased expression of VEGF-R2 in subretinal tissue compared to PBS treated groups. Bar for all images is 25 μm.
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We found that APNpI administration decreased VEGF mRNA and
protein levels in RPE-choroid tissue complex on day 10 post laser in-
jury (Fig. 5). IHC investigation of VEGF expression in naïve animals
showed that RPE cells and choroidal vessels were major sources of
VEGF in the RPE-choroid complex (51.3% and 47.3% of all VEGF in
this tissue, respectively). All other choroidal structures contained
only 1.4% of VEGF. Expression of VEGF increased in RPE cells (26%, G, J,
L), choroidal vessels (50%, Fig. 5G, J, M) and subretinal tissue (26 folds,
Fig. 5G, J, N) on day 10 post laser injury compared to naïve rats. APNpI
administration signiﬁcantly decreased VEGF in RPE cells and vessels
and completely normalized it (Fig. 5H, K, M, N). Treatment with
APNpI reduced (1.6 folds) level of VEGF in subretinal tissue compared
to PBS treated group (Fig. 5H, K, N).
We determined that VEGF-R2 mRNA expression in RPE-choroid
increased 2 folds on day 10 post laser injury compared to the naïve
control (Fig. 6A, C). Administration of APNpI normalized VEGF-R2
level on day 10 after laser. IHC investigation showed that mean intensity
of VEGF-R2 positive immunoﬂuorescence increased in RPE cells and in
subretinal tissue (Fig. 6G, J, L, N) on day 10 post laser injury compared
to the naïve control (Fig. 6F, I, L, N). Administration of APNpI decreased
VEGF-R2 levels in subretinal tissue 4 folds on day 10 post laser injury
and normalized it (Fig. 6H, K, N). Expression of VEGF-R2 in Isolectin IB4
positive vessels was the same on day 10 post laser injury in APNpI andPBS treated groups and was equal to the naïve control (Fig. 6F–K, M).
In vitro study conﬁrmed that APNpI has no effect on expression of
VEGF-R2 mRNA in CECs (Fig. 6E).
3.5. Effect of APNpI on PCNA proliferative index
We investigated PCNA proliferative index in laser spots of PBS and
APNpI treated animals using method of IHC. We found that on day 10
post laser injury APNpI treated rats had signiﬁcantly (4 folds) decreased
PCNA positive nuclei in laser spot (Fig. 7).
4. Discussion
Adiponectin is produced mostly by adipose tissue and present in
blood in high amount [20,27–29]. Adipocyte derived APN represents
the basic level of the hormone necessary to perform its numerous func-
tions [10,27]. Local production of APNby non adipose tissues contributes
to regulation of local processes like inﬂammation, regeneration and
neovascularization [9,10,15]. Adiponectin circulates in the blood in full
length form, globular APN may originate from full form by proteolytic
cleavage [30]. We designed APN peptide I from the globular domain of
APN.
In this study we have shown that medium and large sized choroidal
vessels expressed APN in naïve rats. Formation of CNV after laser injury
was characterized by increased expression of APN in new formed
Fig. 7. APNpI inﬂuence on PCNA proliferative index in laser injured area. Representative images of parafﬁn sections stained by IHC method for PCNA from PBS (A) and APNpI (B) treated
animals. PCNA positive nuclei are purple. Sections were counterstained withMethyl green. (C) A graph showing signiﬁcant decrease of percentage of PCNA positive nuclei in APNpI treated
group compared to PBS injected control. Bar for all images is 25 μm.
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in rat choroid and RPE cells. But only AdipoR1 was up-regulated in RPE
cells and newvessels ofmature CNV.We found in thepresent study that
both APN and its receptors expressed in endothelial cells of the choroid
and cultured CECs. AdipoR1 expression was also found in human and
bovine lines of endothelial cells [14]. AdipoR1 is a receptor mostly for
globular APN and AdipoR2 is for full-length APN [7,27].
To determine the effects of APN in CNV we investigated the role of
APNpI in the rat model of CNV in vivo and on CECs in culture. APNpI
was accumulated in CNV and CECs and colocalized with AdipoR1.
We found that APNpI decreased the size and the number of newly
formed choroidal vessels. APNmay be important in the regulation of an-
giogenesis since increased levels of APNhave anti-angiogenic effects [10].
Possible mechanisms of APN action may include anti-inﬂammatory ac-
tion which involves regulation of pro-inﬂammatory cytokines and
growth factors [7,9,13–18,27].
VEGF and other growth factors promote development of CNV
[3–5]. Reduction of VEGF is a key event in the treatment of AMD [4].
VEGF was found in the proliferating RPE cells, choroidal endothelial
cells, inﬂammatory cells and subretinal tissue [31,32] after induction of
CNV.We investigated the expression of VEGF on day 10 post laser injury
when the network of newvesselswas formed.We found increased levels
of VEGF mRNA and protein in the RPE-choroid tissue complex of rats on
day 10 post laser injury compared to naïve (non-lasered) animals. Under
microscopic examination of IHC stained sections of naïve rats we found
that the VEGF is expressed mostly in the RPE and choroidal vessels. On
day 10 post laser injury we found that the VEGF in RPE and choroidal
vessels had increased however, the most impressive changes were ob-
served in subretinal tissues compared to the choroid of naïve animals.
APNpI treatment normalized expression of VEGF in RPE cells and cho-
roidal vessels and reduced the amount of VEGF in subretinal tissue.
VEGF is involved in cellular proliferation mostly mediated through
its receptor VEGF-R2 [33]. We tested levels of VEGF-R2 and found that
APNpI did not change expression of VEGF-R2 in choroidal vessels and
CECs in culture. However, VEGF-R2 in subretinal tissuewas signiﬁcantly
reduced. This observation shows that reduction of VEGF expression byAPNpI did not induce over-expression of its receptors but reduced
VEGF-R2 expression in subretinal tissues.
Previous studies have shown that the full length APN inhibited
proliferation of endothelial cells in vitro and in vivo [11,14,27]. APN
also inhibited proliferation of other types of cells like vascular smooth
muscle cells [13,34], keratinocytes [35], cancer cells [36–38].
Here we propose the mechanism of anti-angiogenic action of APN
in the rat model of CNV. APNpI accumulates on AdipoR1-positive RPE
cells and choroidal vessels, reduces production and secretion of VEGF,
which leads to low PCNA expression and reduced cell proliferation
thus decreasing formation of new vessels. Our results show that the
APNpI inhibited formation of new choroidal vessels and reduced the
neovascular size and density. Thus in future, the peptide (APNpI) may
be helpful in the treatment of the wet type of AMD in humans.
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